Enoxaparin
Low Molecular Weight Heparin (LMWH) Anticoagulant
Enoxaparin (Clexane) is the first-line, preferred anticoagulant during pregnancy for treating or preventing venous thromboembolism (DVT/PE) and antiphospholipid syndrome. It does NOT cross the placenta.
Enoxaparin (LMWH) does not cross the placenta due to its large molecular weight, making it completely safe for the developing fetus.
Safe. Does not cross placenta or cause embryonic damage.
Safe for long-term thromboprophylaxis.
Safe. Hold dose prior to epidural/delivery as planned by OB.
Large polar molecule cannot pass through syncytiotrophoblast layers. Fetus receives zero drug exposure.
No teratogenicity, no fetal anticoagulation, no fetal bleeding risks.
Standard anticoagulant bleeding risks.
First-line choice for pregnancy anticoagulation.
Enoxaparin is safe for your baby. Continue taking as directed.
- Platelet count monitoring to rule out HIT
- Anti-Xa peak levels if therapeutic dosing is indicated
- Enoxaparin does not cross the placenta and is not secreted in breast milk.
Enoxaparin (Clexane) is the safest blood thinner during pregnancy because it does not cross the placenta to reach your baby.
No. Enoxaparin is too large to cross the placenta, so your baby is completely safe from the drug.
Endorsed by ACCP, ACOG, and RCOG clinical practice guidelines.
-
1
U.S. Food and Drug Administration (FDA) PLLR — FDA Pregnancy and Lactation Labeling Rule & Approved Prescribing Information Database Last updated: Official FDA Standard
-
2
FDA Center for Drug Evaluation and Research (CDER) — FDA MedWatch & Black Box Warning Database Last updated: Official FDA Standard
-
3
ACOG Practice Bulletins & Guidelines — American College of Obstetricians and Gynecologists Clinical Recommendations Last updated: 2025 Clinical Edition
-
4
Briggs Drugs in Pregnancy and Lactation — Reference Guide to Fetal and Neonatal Risk (12th Edition) Last updated: 2025 Clinical Edition